Tripeptide-based inhibitors demonstrate potent in vitro activity against norovirus protease, representing a potential drug target for viral replication.
Potent norovirus protease inhibitors merit further preclinical testing; leaves open translation to clinical antivirals.
The protease of norovirus, an important human pathogen, is essential for the viral replication and, therefore, represents a potential drug target. A series of tripeptide-based inhibitors of the protease were designed, synthesized and tested, among which several potent inhibitors were identified with Ki values as low as 75 nM. The structure–activity relationships of these inhibitors are discussed.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: